{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"title":"complete response rate (GCB DLBCL)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"title":"complete response rate (Non-GCB DLBCL)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"title":"complete response rate (Inconclusive/Not done)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"35"}],"units":"Participants"}],"description":"Responses are tabulated by gene expression profiling (GEP) (germinal center B-cell \\[GCB\\], activated B-cell \\[ABC\\], unclassifiable) and immunohistochemistry \\[IHC\\] (GCB, non-GCB).","groups":[{"description":"Each participant in the dose-finding cohort must have completed at least cycle 1 (or 21 days) of ibrutinib plus rituximab (R)-dose adjusted (da)-etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin (EPOCH). Starting dose of ibrutinib is 560 mg PO.","id":"OG000","title":"Dose-finding Cohort"},{"description":"Each participant in the dose expansion cohort may receive treatment for a maximum of 6 cycles (21-day cycle length) of ibrutinib plus rituximab (R)-dose adjusted (da)-etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin (EPOCH). MTD of ibrutinib is 560 mg PO.","id":"OG001","title":"Dose Expansion Cohort"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants who received study treatment","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Response by Lymphoma Cell-of-origin (COO) Assessment","type":"SECONDARY","unitOfMeasure":"Participants"}